Ulysses Aconitum Biotech is a research-driven biopharmaceutical company with 18+ years of scientific excellence, dedicated to bringing transformative medicines to patients across 38+ countries worldwide.
To discover, develop, and deliver transformative medicines that address serious, life-limiting diseases and bring meaningful therapeutic benefit to patients who have no or inadequate treatment options.
To be recognised as the most innovative biopharmaceutical company in the Middle East and among the top 20 globally, setting the standard for scientific excellence, patient focus, and ethical leadership.
We believe great medicines start with great science. Evidence drives every decision.
Every programme we pursue is selected for its potential to meaningfully improve lives.
We operate with transparency, accountability, and the highest ethical standards.
We bring medicines to patients worldwide, respecting the diversity of communities we serve.
18 years of scientific discovery, regulatory milestones, and patient impact.
First partnership pipeline established
First product marketing authorisation and launch
MENA regional headquarters established in Dubai, UAE
Portfolio reaches 20 marketed products
GCC commercial operations launched
47+ approved products; presence in 38+ countries globally
Experienced leaders driving UAB's mission across science, medicine, regulatory affairs, and commercial operations.